| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We have been reported the usefulness of insulin-like growth factor (IGF) as a therapeutic target using IGF neutralizing antibody. This antibody can neutralize only bioactive IGF activated in the tumor microenvironment and does not affect the physiological molecular form, IGF-IGF binding protein complex. This characteristics of antibody can lead to not only reduction of the systemic adverse effect but also tumor-specific drug delivery. It is essential for the accurate dosage adjustment and prediction of therapeutic and adverse effect to measure the level of bioactive IGF. We successfully develop the novel assay for the detection of bioactive IGF in the blood. Furthermore, we clarified that bioactive IGF-2 was elevated in a case of tumor-associated hypoglycemia except insulin-producing tumor using this assay.
|
